A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
Condition(s):PsoriasisLast Updated:November 8, 2022Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):PsoriasisLast Updated:November 8, 2022Active, not recruiting
Condition(s):Pleural Malignant MesotheliomaLast Updated:April 10, 2020Completed
Condition(s):LymphomaLast Updated:March 20, 2024Recruiting
Condition(s):NeuroblastomaLast Updated:October 31, 2013Completed
Condition(s):Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative NeoplasmsLast Updated:January 22, 2016Completed
Condition(s):Head and Neck Squamous Cell CarcinomaLast Updated:May 27, 2020Unknown status
Condition(s):Prostate CancerLast Updated:February 5, 2013Completed
Condition(s):Asthma, AllergicLast Updated:October 11, 2021Completed
Condition(s):Chronic Rhino-sinusitis; IL-4R; Monoclonal Antibody; BiomarkerLast Updated:June 23, 2022Not yet recruiting
Condition(s):Acute GoutLast Updated:December 14, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.